CGAS and metabolic dysfunction-associated steatotic liver disease: Targeting key immune molecules—such as inhibiting the cGAS–STING pathway, or targeting TLR4, NLRP3, or IL‐1β signaling—has shown promise for improved safety profiles in both ALD and MASLD.